论文部分内容阅读
作者分析1973.1至1976.8四年中美国西南肿瘤组14个机构462例多发性骨髓瘤初治病例应用六种不同化疗方案诱导治疗和两种方案维持治疗的效果,着重注意长春新检的治疗价值。疗效标准以血清骨髓瘤蛋白产生率比治疗前减低75%以上,和尿本周氏蛋白消失,持续2个月以上为有效。1973.1.至1974.9.计235例分三组,每隔四周采用MAP、MCP、MCBP方案各一疗程。用法为M(马法兰)6毫克(MCBP4毫克)/米~2/天×4天,C(环磷酰胺)300毫克(MCP500毫克)/米~2(静)第
The authors analyzed the effect of six different chemotherapy regimens induction therapy and two regimens of maintenance therapy in 462 primary myeloma patients from 14 institutions in the Southwest United States from 1973.1 to 1976.8 during the four years. Emphasis was placed on the therapeutic value of the new Changchun regimen. Efficacy standards to reduce the incidence of serum myeloma protein than before treatment more than 75%, and urine weeks protein disappeared for more than 2 months is valid. From 1973.1 to 1974.9, a total of 235 cases were divided into three groups, and each course of MAP, MCP and MCBP was taken every four weeks. Usage M (melphalan) 6 mg (MCBP4 mg) / m ~ 2 / day × 4 days, C (cyclophosphamide) 300 mg (MCP500 mg) / m ~ 2